These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 31099498)

  • 41. Aqueous Humor Cytokines and Long-Term Response to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema.
    Felfeli T; Juncal VR; Hillier RJ; Mak MYK; Wong DT; Berger AR; Kohly RP; Kertes PJ; Eng KT; Boyd SR; Altomare F; Giavedoni LR; Muni RH
    Am J Ophthalmol; 2019 Oct; 206():176-183. PubMed ID: 30959004
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term follow-up of antivascular endothelial growth factor treatment for diabetic macular oedema: a four-year real-world study.
    Granstam E; Rosenblad A; Modher Raghib A; Granström T; Eriksson JW; Lindholm Olinder A; Leksell J
    Acta Ophthalmol; 2020 Jun; 98(4):360-367. PubMed ID: 31656056
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of ranibizumab, aflibercept, and dexamethasone implant monotherapy in treatment-naive eyes with diabetic macular edema: A 12-month real-life experience.
    Parca O; Cetin EN
    Indian J Ophthalmol; 2024 May; 72(Suppl 3):S453-S458. PubMed ID: 38648453
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Diabetic Macular Edema (BRDME): The BRDME Study, a Randomized Trial.
    Vader MJC; Schauwvlieghe AME; Verbraak FD; Dijkman G; Hooymans JMM; Los LI; Zwinderman AH; Peto T; Hoyng CB; van Leeuwen R; Vingerling JR; Moll AC; van Lith-Verhoeven JJC; Dijkgraaf MGW; Schlingemann RO;
    Ophthalmol Retina; 2020 Aug; 4(8):777-788. PubMed ID: 32362552
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of the New "SAVE" Protocol in Diabetic Macular Edema Over the Course of Anti-VEGF Treatment.
    Reznicek L; Bolz M; Garip A; Kampik A; Kernt M; Mayer WJ
    Curr Eye Res; 2016 Aug; 41(8):1082-1086. PubMed ID: 26580417
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab.
    Ashraf M; Souka AA; ElKayal H
    Ophthalmic Surg Lasers Imaging Retina; 2017 Mar; 48(3):230-236. PubMed ID: 28297035
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema.
    Wong Y; Steel DHW; Habib MS; Stubbing-Moore A; Bajwa D; Avery PJ;
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):733-742. PubMed ID: 27957600
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravitreal aflibercept for diabetic macular oedema: Moorfields' real-world 12-month visual acuity and anatomical outcomes.
    Lukic M; Williams G; Shalchi Z; Sim D; Patel PJ; Keane PA; Hykin PG; Sivaprasad S; Menon D; Bruynseels A; Hamilton RD; Rajendram R
    Eur J Ophthalmol; 2020 May; 30(3):557-562. PubMed ID: 30808179
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Macular cystic changes as predictive factor for the recurrence of macular oedema in branch retinal vein occlusion.
    Tilgner E; Dalcegio Favretto M; Tuisl M; Wiedemann P; Rehak M
    Acta Ophthalmol; 2017 Nov; 95(7):e592-e596. PubMed ID: 28266152
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Higher-Order Assessment of OCT in Diabetic Macular Edema from the VISTA Study: Ellipsoid Zone Dynamics and the Retinal Fluid Index.
    Ehlers JP; Uchida A; Hu M; Figueiredo N; Kaiser PK; Heier JS; Brown DM; Boyer DS; Do DV; Gibson A; Saroj N; Srivastava SK
    Ophthalmol Retina; 2019 Dec; 3(12):1056-1066. PubMed ID: 31473172
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice.
    Holekamp NM; Campbell J; Almony A; Ingraham H; Marks S; Chandwani H; Cole AL; Kiss S
    Am J Ophthalmol; 2018 Jul; 191():83-91. PubMed ID: 29684329
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Longitudinal Panretinal Leakage and Ischemic Indices in Retinal Vascular Disease after Aflibercept Therapy: The PERMEATE Study.
    Figueiredo N; Srivastava SK; Singh RP; Babiuch A; Sharma S; Rachitskaya A; Talcott K; Reese J; Hu M; Ehlers JP
    Ophthalmol Retina; 2020 Feb; 4(2):154-163. PubMed ID: 31757691
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intravitreal injection of a Rho-kinase inhibitor (fasudil) combined with bevacizumab versus bevacizumab monotherapy for diabetic macular oedema: a pilot randomised clinical trial.
    Ahmadieh H; Nourinia R; Hafezi-Moghadam A; Sabbaghi H; Nakao S; Zandi S; Yaseri M; Tofighi Z; Akbarian S
    Br J Ophthalmol; 2019 Jul; 103(7):922-927. PubMed ID: 30150280
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab.
    Konidaris V; Al-Hubeshy Z; Tsaousis KT; Gorgoli K; Banerjee S; Empeslidis T
    Int Ophthalmol; 2018 Feb; 38(1):207-213. PubMed ID: 28405787
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of the effect of combined intravitreal ranibizumab injection and sub-tenon steroid injection in the treatment of resistant diabetic macular edema.
    Eriş E; Perente I; Vural E; Vural A; Seymen Z; Celebi ARC; Erdogan G; Ozkaya A; Artunay O
    Int Ophthalmol; 2019 Jul; 39(7):1575-1580. PubMed ID: 29943100
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning: A Post Hoc Analysis of a Randomized Clinical Trial.
    Roberts PK; Vogl WD; Gerendas BS; Glassman AR; Bogunovic H; Jampol LM; Schmidt-Erfurth UM
    JAMA Ophthalmol; 2020 Sep; 138(9):945-953. PubMed ID: 32722799
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Retinal Layers Changes in Patients with Diabetic Macular Edema Treated with Intravitreal Anti-VEGF Agents: Long-Term Outcomes of a Spectral-Domain OCT Study.
    Chatziralli I; Kazantzis D; Theodossiadis G; Theodossiadis P; Sergentanis TN
    Ophthalmic Res; 2021; 64(2):230-236. PubMed ID: 32564022
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ranibizumab treatment improves diabetic macular oedema without influencing retinal oximetry parameters.
    Takasago Y; Fujita T; Nakano Y; Osaka R; Miyake M; Muraoka Y; Tsujikawa A
    Acta Ophthalmol; 2019 Dec; 97(8):e1048-e1053. PubMed ID: 31127694
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Three-dimensional analysis of morphologic changes and visual outcomes in diabetic macular edema.
    Lee H; Kang KE; Chung H; Kim HC
    Jpn J Ophthalmol; 2019 May; 63(3):234-242. PubMed ID: 30783942
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Decrease in the number of microaneurysms in diabetic macular edema after anti-vascular endothelial growth factor therapy: implications for indocyanine green angiography-guided detection of refractory microaneurysms.
    Mori K; Yoshida S; Kobayashi Y; Ishikawa K; Nakao S; Hisatomi T; Haruta M; Isihibashi T; Sonoda KH
    Graefes Arch Clin Exp Ophthalmol; 2020 Apr; 258(4):735-741. PubMed ID: 31960130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.